Ophthalmic artery Doppler at 36 weeks' gestation in prediction of pre‐eclampsia: validation and update of previous model
Authors: Mansukhani T. , Wright A. , Arechvo A. , Laich A. , Iglesias M. , Charakida M. , Nicolaides K. H. 
Published: August 2023

ABSTRACTObjectiveTo validate and extend a model incorporating maternal ophthalmic artery Doppler at 35–37 weeks' gestation in the prediction of subsequent development of pre‐eclampsia (PE).MethodsThis was a prospective validation study of screening for PE (defined according to the 2019 American College of Obstetricians and Gynecologists criteria) by maternal ophthalmic artery peak systolic velocity (PSV) ratio in 6746 singleton pregnancies undergoing routine care at 35 + 0 to 36 + 6 weeks' gestation (validation dataset). Additionally, the data from the validation dataset were combined with those of 2287 pregnancies that were previously used for development of the model (training dataset), and the combined data were used to update the original model parameters. The competing‐risks model was used to estimate the individual patient‐specific risk of delivery with PE at any time and within 3 weeks from assessment by a combination of maternal demographic characteristics and medical history with PSV ratio alone and in combination with the established PE biomarkers of mean arterial pressure (MAP), uterine artery pulsatility index (UtA‐PI), serum placental growth factor (PlGF) and serum soluble fms‐like tyrosine kinase‐1 (sFlt‐1). We evaluated the predictive performance of the model by examining, first, the ability to discriminate between the PE and non‐PE groups using the area under the receiver‐operating‐characteristics curve and the detection rate (DR) at fixed screen‐positive (SPR) and false‐positive rates of 10% and, second, calibration by measuring the calibration slope and calibration‐in‐the‐large. McNemar's test was used to compare the performance of screening by a biophysical test (maternal factors, MAP, UtA‐PI and PSV ratio) vs a biochemical test (maternal factors, PlGF and sFlt‐1), low PlGF concentration (< 10th percentile) or high sFlt‐1/PlGF concentration ratio (> 90th percentile).ResultsIn the validation dataset, the performance of screening by maternal factors and PSV ratio for delivery with PE within 3 weeks and at any time after assessment was consistent with that in the training dataset, and there was good agreement between the predicted and observed incidence of PE. In the combined data from the training and validation datasets, good prediction for PE was achieved in screening by a combination of maternal factors, MAP, UtA‐PI, PlGF, sFlt‐1 and PSV ratio, with a DR, at a 10% SPR, of 85.0% (95% CI, 76.5–91.4%) for delivery with PE within 3 weeks and 65.7% (95% CI, 59.2–71.7%) for delivery with PE at any time after assessment. The performance of a biophysical test was superior to that of screening by low PlGF concentration or high sFlt‐1/PlGF concentration ratio but not significantly different from the performance of a biochemical test combining maternal factors with PlGF and sFlt‐1 for both PE within 3 weeks and PE at any time after assessment.ConclusionMaternal ophthalmic artery PSV ratio at 35–37 weeks' gestation in combination with other biomarkers provides effective prediction of subsequent development of PE. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.